“‘In patent law, much turns on the nitty-gritty details. There’s nothing grittier than the issue’ raised in the Supreme Court case, Robin Feldman, a law professor at the University of California, Hastings, told STAT. ‘It matters a lot. It matters a lot for pharma.’”
The full article can be viewed here.